Maqola

Gene Expression Signature–Based Prognostic Risk Score in Gastric Cancer

Y. ChoiKorean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, DaejeonJae Yun LimDepartments of Medical Oncology, Surgery, and Pathology, Yonsei University College of Medicine, SeoulJae‐Ho CheongJeonbuk National UniversityYun‐Yong ParkDepartments of Medical Oncology, Surgery, and Pathology, Yonsei University College of Medicine, SeoulSe-Lyun YoonDepartments of Medical Oncology, Surgery, and Pathology, Yonsei University College of Medicine, SeoulSoo Mi KimKorean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, DaejeonSang-Bae KimAuthors' Affiliations: Departments of 1Systems Biology, 2Thoracic/Head and Neck Medical Oncology, and 3Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Departments of 4Medical Oncology, 5Surgery, and 6Pathology, Yonsei University College of Medicine, Seoul; 7Department of Biological Science, Dong-A University, Busan; 8Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon; and 9Department of Physiology, Chonbuk National University Medical School and Hospital, Jeonju, KoreaHoguen KimDepartment of Biological Science, Dong-A University, BusanSoon Won HongAuthors' Affiliations: Departments of 1Systems Biology, 2Thoracic/Head and Neck Medical Oncology, and 3Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Departments of 4Medical Oncology, 5Surgery, and 6Pathology, Yonsei University College of Medicine, Seoul; 7Department of Biological Science, Dong-A University, Busan; 8Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon; and 9Department of Physiology, Chonbuk National University Medical School and Hospital, Jeonju, KoreaYoung Nyun ParkAuthors' Affiliations: Departments of 1Systems Biology, 2Thoracic/Head and Neck Medical Oncology, and 3Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Departments of 4Medical Oncology, 5Surgery, and 6Pathology, Yonsei University College of Medicine, Seoul; 7Department of Biological Science, Dong-A University, Busan; 8Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon; and 9Department of Physiology, Chonbuk National University Medical School and Hospital, Jeonju, KoreaSung Hoon NohDepartments of Medical Oncology, Surgery, and Pathology, Yonsei University College of Medicine, SeoulEun Sung ParkAuthors' Affiliations: Departments of 1Systems Biology, 2Thoracic/Head and Neck Medical Oncology, and 3Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; Departments of 4Medical Oncology, 5Surgery, and 6Pathology, Yonsei University College of Medicine, Seoul; 7Department of Biological Science, Dong-A University, Busan; 8Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon; and 9Department of Physiology, Chonbuk National University Medical School and Hospital, Jeonju, KoreaIn‐Sun ChuDepartment of Physiology, Chonbuk National University Medical School and Hospital, Jeonju, KoreaWaun Ki HongDong-A UniversityJaffer A. AjaniDepartment of Biological Science, Dong-A University, BusanJu‐Seog LeeKorean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon

2011en

ABI

Annotatsiya

PURPOSE: Despite continual efforts to develop a prognostic model of gastric cancer by using clinical and pathologic parameters, a clinical test that can discriminate patients with good outcomes from those with poor outcomes after gastric cancer surgery has not been established. We aim to develop practical biomarker-based risk score that can predict relapse of gastric cancer after surgical treatment. EXPERIMENTAL DESIGN: Microarray technologies were used to generate and analyze gene expression profiling data from 65 gastric cancer patients to identify biomarker genes associated with relapse. The association of expression patterns of identified genes with relapse and overall survival was validated in independent gastric cancer patients. RESULTS: We uncovered two subgroups of gastric cancer that were strongly associated with the prognosis. For the easy translation of our findings into practice, we developed a scoring system based on the expression of six genes that predicted the likelihood of relapse after curative resection. In multivariate analysis, the risk score was an independent predictor of relapse in a cohort of 96 patients. We were able to validate the robustness of the six-gene signature in an additional independent cohort. CONCLUSIONS: The risk score derived from the six-gene set successfully prognosticated the relapse of gastric cancer patients after gastrectomy.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1158/1078-0432.ccr-10-2180

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba